EAU PCa 2018: What Urologists Need to Know About Radiotherapy

Milan, Italy (UroToday.com) Dr. Mason and Dr. Bossi, two radiation oncologists, gave a presentation on what is important for urologists to know about radiotherapy. There are several possible reasons why urologists generally resent radiotherapy for prostate cancer. They might think it is less effective, more toxic, causes secondary cancers, makes it difficult to perform surgery afterward, too expensive, and it mandates being treated with hormones.

EAU PCa 2018: Active Surveillance: Patient Selection and Follow-Up

Milan, Italy (UroToday.com) A session on active surveillance was given by Dr. Roobol and Dr. Bratt. The era of active surveillance started almost 20 years ago. The initial phase was followed by a histology and biology phase, and currently, we are in an MRI phase.

EAU PCa 2018: Technical Aspects of Open and Robotic Radical Prostatectomy

Milan, Italy (UroToday.com)  Dr. Graefen and Dr. van der Poel conducted a session on the technical aspects of open and robotic radical prostatectomy.  Although the PROTECT trial randomizing patients with localized prostate cancer to either surgery, radiotherapy, or active monitoring, did not show any difference in the progression and prostate cancer-specific survival between the different groups, it is important to note that primary treatment failure occurred in 3.2% and 10% of patients treated with surgery and radiotherapy, respectively. 1

EAU PCa 2018: Salvage Treatment for Recurrent Disease

Milan, Italy (UroToday.com) Dr. Briganti gave an overview of the role of salvage treatment for recurrent prostate cancer. Three main topics were discussed, including salvage radiotherapy, salvage radical prostatectomy, and salvage lymph node dissection. The first topic discussed was early salvage radiotherapy for prostate cancer. There are many retrospective studies and a few prospective studies on the role of salvage radiotherapy after radical prostatectomy with negative nodes. In contrast, there are very few studies on the scenario when there are positive nodes at radical prostatectomy.

EAU PCa 2018: Genomics in Prostate Cancer, When and How to Use It

Milan, Italy (UroToday.com) Dr. Waltz and Dr. Gerritsen presented their view on the usage of genomics in prostate cancer in 2018. First, it is important to understand when we should apply genomic testing in prostate cancer. This should be applied in screening, initial diagnosis, initial biopsy, repeat biopsy, classification after biopsy (before initiating active surveillance), and classification after treatment. There are multiple tests available for this purpose, and these were summarized in this discussion.

EAU PCa 2018: Imaging of Local Relapse After Local Treatment of Prostate Cancer

Milan, Italy (UroToday.com) Dr. Villeirs began discussing the imaging findings in post-radical prostatectomy patients. Since the prostate has been removed, there is a resulting descent of the bladder base into the empty prostate bed, as shown in Figure 1.

EAU PCa 2018: How to Use PSA in 2018

Milan, Italy (UroToday.com) Dr. Mottet and Dr. Stranne discussed PSA and its various roles in screening, local treatment and systemic treatment. The discussion began with a short explanation of what exactly is PSA. PSA is a protease, and a member of the Kallikrein family also called human kallikrein peptidase 3 (HK3).
Page 2 of 3

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.